Global Atypical Hemolytic Uremic Syndrome Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Atypical Hemolytic Uremic Syndrome Market was valued at $1.4 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 5.5% CAGR, to an estimated market size of $1.9 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The Atypical Hemolytic Uremic Syndrome (aHUS) market encompasses the diagnosis, management, and therapeutic treatment of a rare, life-threatening genetic disorder characterized by chronic, uncontrolled activation of the complement system, resulting in thrombotic microangiopathy (TMA), hemolytic anemia, and acute renal impairment.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Atypical Hemolytic Uremic Syndrome Market in the period 2025-30:
- The market is experiencing a significant shift from intravenous infusions to more convenient subcutaneous and oral formulations to reduce patient treatment burden.
- The entry of eculizumab biosimilars is expected to disrupt traditional pricing models and increase competition within the established C5 inhibitor segment.
- Advancements in genetic screening and complement activity assays are enabling earlier and more accurate diagnosis, expanding the treated patient pool.
- Pharmaceutical companies are increasingly utilizing cross-indication platforms to develop complement-targeting drugs that address multiple rare diseases simultaneously.
- Regulatory support through orphan drug designations and expedited approval pathways continues to incentivize R&D investment in the rare disease space.
- There is a growing clinical focus on personalized medicine, tailoring therapeutic interventions based on specific genetic mutations and individual patient profiles.
- Market competition is evolving from simple mechanism-of-action differentiation toward optimizing dosing frequency and total cost of care.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- C5 Inhibitors (Monoclonal Antibodies)
- Next-Generation & Oral Therapies
- Supportive Care & Plasma Therapy